eRapport

Researcher grant - The global health issue of female genital schistosomiasis and individualised patient management

Prosjekt
Prosjektnummer
2016055
Ansvarlig person
Eyrun F Kjetland
Institusjon
Oslo universitetssykehus HF
Prosjektkategori
Forskerstipend
Helsekategori
Infection, Reproductive Health and Childbirth
Forskningsaktivitet
1. Underpinning, 3. Prevention
Rapporter
2022 - sluttrapport
Around 250 million people are infected with schistosomiasis (Bilharzia), and most of these have S. haematobium, which also causes problems in the genital tract. As a consequence of the broken mucosal barrier, women with female genital schistosomiasis (FGS) may be at risk of HIV, infertility, discharge, and dyspareunia. In adult women Female Genital Schistosomiasis has been found to be refractory to treatment. In this consortium we have explored FGS broadly. The natural history of FGS was not known and deeper knowledge in this field will help us determine the best timing for treatment. Furthermore, in this project period we lay the foundation for the development of a diagnostic tools that can be used in rural areas where the disease is endemic, but also for nonendemic areas where the disease is rare. In the project period we completed a study in KwaZulu-Natal, South Africa where we investigated teenagers willing to undergo gynaecological examinations. Three PhDs on this are completed, one more on the way ase well as several publications. We have had multiple application and writing workshops that have resulted in some grants, the most important being DUALSAVE-FGS of 80 million NOK which will engage health policy makers, developers of curricula (medical and nursing schools) the next 4 years. We are now working with another 8 institutions and are 27 senior scientists on board, thanks to the support from HSØ. Female Genital Schistosomiasis is not addressed in the health systems. In the new DUALSAVE-FGS project we have started to address medical school and nursing curricula, patient management protocols and policy documents. A score of social scientists are on board, in addition to our old medical team. A clinical trial will be performed with our new partner Costas Balas in QCELL, a small enterprise, that has produced a new type of low-cost colposcope for FGS. The World Health Organisation and the Ministries of Health in three countries are participating in the forthcoming work.

The candidate spent several months in South Africa and three weeks in Eswatini to prepare a new grant from EU, where the candidate (Oslo University Hospital) is the coordinator. The grant of almost 80 million NOK "DUALSAVE-FGS" will be continuing the stewardship of FGS in Southern Africa.

2021
The activities are perfectly timed with requests from the scientific community and perfectly aligned with the WHO policies. If the study hypotheses are confirmed we – as health professionals – have a simple tool for use in future research and clinical management of patients with Female Genital Schistosomiasis.The research was designed in direct communication with the WHO and with advice from key stakeholders such and Ministries of Health, gynaecologists and the WHO pocket atlas co-authors [6]. The goal of our project is to contribute to a reduction in the global burden of FGS through improved knowledge about the prevention of gynaecological lesions and improved diagnosis. The utilization of the study results will therefore provide continued work for researchers. This information can be of use in current cervical cancer screening and schistosomiasis control programmes resulting in improved strategies for treatment in several countries. For example, South Africa has special regulatory requirements that hinder the availability of inexpensive anti-schistosomal treatment. Oslo University Hospital, University of KwaZulu-Natal and Centre for Bilharzia and Tropical Health Research have been working on this issue to try to prepare the way for mass-treatment as a general policy (by publication in press, dialogue with the National Department of Health, and lobbying). We are in close contact with WHO as well as relevant research projects, and managers of cervical cancer screening and schistosomiasis control programmes in order to ensure that research findings can result in improved strategies for treatment and improved reproductive health among women in Sub-Saharan Africa. In addition, a number of questions should be explored by researchers who could make our diagnostic progress to e.g. determine prognosis or reasons behind dyspareunia. For cervical cancer screening, the WHO now recommends using the PCR - “test for HPV-and-treat” -approach where possible. In contrast, there are no official recommendations on how to diagnose FGS, and PCR for genital schistosomiasis does not necessarily provide enough information for the diagnosis for FGS. In the clinical screening, clinicians may mistake FGS for cervical cancer. The potential for over-/undertreatment due to the subjectivity with colposcopy shows the need for accessible and accurate screening methods. Millions of people live with the social and psychological repercussions of FGS, mistaken diagnosis, misinformation, physical pain, bleeding, and malodour. Yet in some areas FGS may be the most common gynaecological lesion, more common than sexually transmitted diseases, affecting vulnerable populations from the girl child, through adolescence, womanhood and into old age. The development of our diagnostic tools and treatment depends on translational and multi-disciplinary integrated research networks, crucial in poorer parts of the world, such as Africa. If found to be effective, will be scaled up for implementation under the national public health programs. We have reason to believe that several cervical screening programmes will make this possible within the next decade.

South Africa, Eswatini and Zambia. The stays prepared the ensuing projects starting in 2023 and consolidated collaboration especially on diagnostic imaging and management.

2020
Around 250 million people are infected with schistosomiasis (Bilharzia), and most of these have S. haematobium, which also causes problems in the genital tract. As a consequence of the broken mucosal barrier, women with female genital schistosomiasis (FGS) may be at risk of HIV, infertility, discharge, and dyspareunia. In adult womenFemale Genital Schistosomiasis has been found to be refractory to treatment. We have therefore started a study in KwaZulu-Natal, South Africa where we are investigating teenagers willing to undergo gynaecological examinations. In this consortium we have explores FGS broadly. The natural history of FGS is not known and deeper knowledge in this field could determine the best timing for treatment. It could help provide information to the patient, discharge may be chronic and susceptibility to HIV may possibly be altered. We are currently exploring if the disease is reversible. We are developing a diagnostic tools that can be used in rural areas where the disease is endemic, but also for non-endemic areas where the disease is rare. The international collaboration and exchange of knowledge will benefit Norwegian and African researchers alike. The candidates will receive advice from senior scientists with longstanding cross-professional experience. In a growing network of experts we have improved, despite the covid pandemic, the possibilities for exchange and transfer of best practice. Currently, the 6th PhD candidate is working on her project and 19 Masters students are contributing.

The candidate was in KwaZulu-Natal, South Africa for 2.5 months, as part of the data collection and collaboration with University of KwaZulu-Natal. The stay was cut short by the covid pandemic but the tutoring work has continued through virtual meetings and through the involvement of a new partner in Canada for the development of a diagnostic tool that will be tested in three Francophone countries in Africa, namely Mali, Guinea Bissau and DR Congo. This is crucial for scale-up.

2019
Female Genital Schistosomiasis (FGS) affects millions of females and has been hypothesised to be the main cause of HIV transmission in females of Sub-Saharan Africa. Health professionals can neither diagnose nor treat.Around 250 million people are infected with schistosomiasis (Bilharzia), and most of these have S. haematobium, which also causes problems in the genital tract. As a consequence of the broken mucosal barrier, women with FGS may be at risk of HIV, infertility, discharge, and dyspareunia. In adult women FGS has been found to be refractory to treatment. We have conducted a study on adolescent girls and young women willing to undergo gynaecological examinations. Our consortium will explore FGS broadly in KwaZulu-Natal, South Africa. The natural history of FGS is not known and deeper knowledge in this field could determine the best timing for treatment. It could help provide information to the patient, discharge may be chronic and susceptibility to HIV may possibly be altered. We seek to explore if the disease is reversible and wish to find diagnostic tools that can be used in rural areas where the disease is endemic, but also for non-endemic areas where the disease is rare. In the age of globalisation, international collaboration and exchange of knowledge will benefit Norwegian and African researchers alike. The candidates will receive advice from senior scientists with longstanding cross-professional experience. In a growing network of experts we will strengthen the possibilities for exchange and transfer of best practice. This conveyance of expertise will lift the quality of research to international levels. This year we have been reaping the harvest from the sample and information collection that was completed as per agreement with HSØ in 2018. In 2019 laboratory analyses were on the way. Several new candidates have embarked on analyses and writing. The data is currently being entered, cleaned or analysed; writing has commenced.

The candidate has been in KwaZulu-Natal, South Africa for 5 months, as part of the data collection, collaboration with University of KwaZulu-Natal. International experience is crucial for ensuring external project funding and implementation. The overseas stay gave her valuable experience and the opportunity to establish contacts and build networks, conference participation, course and seminar participation.

2018
Female genital schistosomiasis (FGS) affects millions of females and has been hypothesised to be the main cause of HIV transmission in females of Sub-Saharan Africa. Health professionals can neither diagnose nor treat. The researcher has created the WHO pocket atlas for FGS and published more than half of the articles on FGS worldwide.Around 250 million people are infected with schistosomiasis (Bilharzia), and most of these have S. haematobium, which also causes problems in the genital tract. As a consequence of the broken mucosal barrier, women with female genital schistosomiasis (FGS) may be at risk of HIV, infertility, discharge, and dyspareunia. In adult women FGS has been found to be refractory to treatment. We have therefore started a study in KwaZulu-Natal, South Africa where we are investigating teenagers willing to undergo gynaecological examinations. In a new consortium we will explore FGS broadly. The natural history of FGS is not known and deeper knowledge in this field could determine the best timing for treatment. It could help provide information to the patient, discharge may be chronic and susceptibility to HIV may possibly be altered. We seek to explore if the disease is reversible and wish to find diagnostic tools that can be used in rural areas where the disease is endemic, but also for non-endemic areas where the disease is rare. In the age of globalisation, international collaboration and exchange of knowledge will benefit Norwegian and African research alike. The candidates will receive advice from senior scientists with longstanding cross-professional experience. In a growing network of experts we will strengthen the possibilities for exchange and transfer of best practice. This conveyance of expertise will lift the quality of research to international levels. This year the entire field work has been financed by this grant as per agreement with HSØ in October 2016. The last year the researcher grant has allowed the researcher to complete the fieldwork on S. mansoni as a cause for genital lesions. FGS has been explored as a risk factor for human papillomavirus and also other sexually transmitted infections, some of this has now been published but more analyses of the existing data are necessary. Furthermore, many case reports indicate that FGS lesions could imitate HPV lesions but this will be explored now. Last but not least we have done field work on female genital schistosomiasis as a risk factor for HIV. The data is currently being entered and we will explore if further recruitment is necessary. In the course of the year 2017 our landlord of the clinic passed away and the buildings were sold. This made a crisis mid-year where we were rescued by a generous donation from the Royal Norwegian Embassy in Pretoria to purchase a new research site. This opens the door for researcher exchange, new research projects, collaboration with Department of Health, with the local hospitals

3 opphold i 2018, (1) åpning av ny forskningsstasjon "BRIGHT Academy" http://brightresearch.org/, (2) datavasking, skriving, holdt 3 kurs og jobbet for å få til utvidet samarbeide med helsedepartementet, (3) skriving, forberedelse til en doktorgradskandidats laboratorieanalyser (identifisere kasus, finne prøvene, kjøpe reagenser, planlegge prosedyrer), veilede en annen doktorgradskandidat i sluttfasen.

2017
Female genital schistosomiasis(FGS) affects millions of females and has been hypothesised to be the main cause of HIV transmission in females of Sub-Saharan Africa. Health professionals can neither diagnose nor treat. The researcher has created the WHO pocket atlas for FGS and published more than half of the articles on FGS worldwide.Around 250 million people are infected with schistosomiasis (Bilharzia), and most of these have S. haematobium, which also causes problems in the genital tract. As a consequence of the broken mucosal barrier, women with female genital schistosomiasis (FGS) may be at risk of HIV, infertility, discharge, and dyspareunia. In adult women FGS has been found to be refractory to treatment. We have therefore started a study in KwaZulu-Natal, South Africa where we are investigating teenagers willing to undergo gynaecological examinations. In a new consortium we will explore FGS broadly. The natural history of FGS is not known and deeper knowledge in this field could determine the best timing for treatment. It could help provide information to the patient, discharge may be chronic and susceptibility to HIV may possibly be altered. We seek to explore if the disease is reversible and wish to find diagnostic tools that can be used in rural areas where the disease is endemic, but also for non-endemic areas where the disease is rare. In the age of globalisation, international collaboration and exchange of knowledge will benefit Norwegian and African research alike. The candidates will receive advice from senior scientists with longstanding cross-professional experience. In a growing network of experts we will strengthen the possibilities for exchange and transfer of best practice. This conveyance of expertise will lift the quality of research to international levels. This year the entire field work has been financed by this grant as per agreement with HSØ in October 2016. The last year the researcher grant has allowed the researcher to complete the fieldwork on S. mansoni as a cause for genital lesions. FGS has been explored as a risk factor for human papillomavirus and also other sexually transmitted infections, some of this has now been published but more analyses of the existing data are necessary. Furthermore, many case reports indicate that FGS lesions could imitate HPV lesions but this will be explored now. Last but not least we have done field work on female genital schistosomiasis as a risk factor for HIV. The data is currently being entered and we will explore if further recruitment is necessary. In the course of the year 2017 our landlord of the clinic passed away and the buildings were sold. This made a crisis mid-year where we were rescued by a generous donation from the Royal Norwegian Embassy in Pretoria to purchase a new research site. This opens the door for researcher exchange, new research projects, collaboration with Department of Health, with the local hospitals
2016
The grant aims to ensure stewardship of research on FGS, roll-out of the current knowledge, and international continuity with the aim to enable correct clinical management of FGS for the travelled and multi-cultural patients whilst tutorin PhD and Masters students to become experienced, international, flexible, and high-achieving researchersGenital lesions caused by the parasite Schistosoma haematobium (Bilharzia) are commonly found in females in rural Africa where they do not have access to clean water. Children, as young as 10 years of age, have intravaginal lesions due to Female Genital Schistosomiasis (FGS). Studies have shown a three-fold higher prevalence of HIV in women with FGS. Mass treatment has been implemented in some African countries. However, unexpectedly in the only study on treatment of FGS it was found to be ineffective. The grant will be used to expand and build on this work. The timing of interventions to prevent chronic FGS will be determined through a prospective study. Furthermore, we will explore if treatment of young adolescent women prevents HIV transmission. Diagnostic tools will be explored. The grant will make it possible to explore new avenues and teach so that more researchers can be involved. In a cross-sectional study design we aim to (1) Explore if FGS is associated with sexually transmitted diseases, especially HPV. (2) Determine if S. mansoni infection leads to genital manifestations. (3) Develop and test colourimetric and textural digital software analysis for the diagnosis of FGS. In the long term the proposed grant will ensure continued stewardship of research on FGS, roll-out of current knowledge, and international continuity. It will (1) enable correct clinical management of FGS in both endemic and non-endemic areas and (2) can contribute to better quality of health services for the travelled and multi-cultural patients. International research will increase the quality of the research and will ultimately benefit all patients. In the age of globalisation and migration, international collaboration and exchange of knowledge will benefit travellers and patients of multi-national origin, of which Oslo University Hospital has the largest population in Norway. In order to provide patient-centered, timely and correct diagnosis, and access to second opinion, health services must have rich knowledge of international medicine and collaborations with international clinicians and scientists. The diagnostic tools of many tropical diseases are unknown amongst Norwegian doctors and gynaecologists. Knowledge is needed to serve immigrants with infections and reproductive health problems; especially, if this puts them at risk of life-long suffering as is the case with genital schistosomiasis. This collaborative effort encompasses the most inclusive research on female genital schistosomiasis (FGS) to date. The research questions were designed in direct communication with the World Health Organisation (WHO) and will generate pragmatic recommendations for public health interventions and clinical practice. The researcher aims to provide ways to diagnose the disease in areas where the disease is rare or unknown. Furthermore, this research grant will enable long term: stewardship in rolling out the information so that the clinicians know how to manage patients in and from schistosomiasis endemic areas.
Vitenskapelige artikler
Sturt AS, Webb EL, Phiri CR, Mapani J, Mudenda M, Himschoot L, Kjetland EF, Mweene T, Levecke B, van Dam GJ, Corstjens PLAM, Ayles H, Hayes RJ, Francis SC, van Lieshout L, Cools P, Hansingo I, Bustinduy AL

The Presence of Hemoglobin in Cervicovaginal Lavage Is Not Associated With Genital Schistosomiasis in Zambian Women From the BILHIV Study.

Open Forum Infect Dis 2022 Dec;9(12):ofac586. Epub 2022 des 16

PMID: 36540382

Nemungadi TG, Furumele TE, Gugerty MK, Djirmay AG, Naidoo S, Kjetland EF

Establishing and Integrating a Female Genital Schistosomiasis Control Programme into the Existing Health Care System.

Trop Med Infect Dis 2022 Nov 16;7(11). Epub 2022 nov 16

PMID: 36422933

, Garcia-Gallo E, Merson L, Kennon K, Kelly S, Citarella BW, Fryer DV, Shrapnel S, Lee J, Duque S, Fuentes YV, Balan V, Smith S, Wei J, Gonçalves BP, Russell CD, Sigfrid L, Dagens A, Olliaro PL, Baruch J, Kartsonaki C, Dunning J, Rojek A, Rashan A, Beane A, Murthy S, Reyes LF

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19.

Sci Data 2022 Jul 30;9(1):454. Epub 2022 jul 30

PMID: 35908040

Sang HC, Mwinzi PNM, Odiere MR, Onkanga I, Rawago F, Pillay P, Kjetland EF

Absence of lower genital tract lesions among women of reproductive age infected with Schistosoma mansoni: A cross-sectional study using a colposcope in Western Kenya.

PLoS Negl Trop Dis 2022 Jul;16(7):e0010473. Epub 2022 jul 8

PMID: 35802746

Ellingjord-Dale M, Kalleberg KT, Istre MS, Nygaard AB, Brunvoll SH, Eggesbø LM, Dahl JA, Kjetland EF, Ursin G, Søraas A

The use of public transport and contraction of SARS-CoV-2 in a large prospective cohort in Norway.

BMC Infect Dis 2022 Mar 14;22(1):252. Epub 2022 mar 14

PMID: 35287611

Sturt AS, Webb EL, Himschoot L, Phiri CR, Mapani J, Mudenda M, Kjetland EF, Mweene T, Levecke B, van Dam GJ, Corstjens PLAM, Ayles H, Hayes RJ, van Lieshout L, Hansingo I, Francis SC, Cools P, Bustinduy AL

Association of Female Genital Schistosomiasis With the Cervicovaginal Microbiota and Sexually Transmitted Infections in Zambian Women.

Open Forum Infect Dis 2021 Sep;8(9):ofab438. Epub 2021 aug 22

PMID: 34557562

Søraas A, Kalleberg KT, Dahl JA, Søraas CL, Myklebust TÅ, Axelsen E, Lind A, Bævre-Jensen R, Jørgensen SB, Istre MS, Kjetland EF, Ursin G

Persisting symptoms three to eight months after non-hospitalized COVID-19, a prospective cohort study.

PLoS One 2021;16(8):e0256142. Epub 2021 aug 26

PMID: 34437579

Sturt AS, Webb EL, Phiri CR, Mudenda M, Mapani J, Kosloff B, Cheeba M, Shanaube K, Bwalya J, Kjetland EF, Francis SC, Corstjens PLAM, van Dam GJ, van Lieshout L, Hansingo I, Ayles H, Hayes RJ, Bustinduy AL

Female Genital Schistosomiasis and HIV-1 Incidence in Zambian Women: A Retrospective Cohort Study.

Open Forum Infect Dis 2021 Jul;8(7):ofab349. Epub 2021 jun 30

PMID: 34337098

Livingston M, Pillay P, Zulu SG, Sandvik L, Kvalsvig JD, Gagai S, Galappaththi-Arachchige HN, Kleppa E, Ndhlovu P, Vennervald B, Gundersen SG, Taylor M, Kjetland EF

Mapping Schistosoma haematobium for Novel Interventions against Female Genital Schistosomiasis and Associated HIV Risk in KwaZulu-Natal, South Africa.

Am J Trop Med Hyg 2021 05 03;104(6):2055-2064. Epub 2021 mai 3

PMID: 33939629

Sturt AS, Webb EL, Patterson C, Phiri CR, Mweene T, Kjetland EF, Mudenda M, Mapani J, Mutengo MM, Chipeta J, van Dam GJ, Corstjens PLAM, Ayles H, Hayes RJ, Hansingo I, Cools P, van Lieshout L, Helmby H, McComsey GA, Francis SC, Bustinduy AL

Cervicovaginal Immune Activation in Zambian Women With Female Genital Schistosomiasis.

Front Immunol 2021;12():620657. Epub 2021 mar 2

PMID: 33737927

Søfteland S, Sebitloane MH, Taylor M, Roald BB, Holmen S, Galappaththi-Arachchige HN, Gundersen SG, Kjetland EF

A systematic review of handheld tools in lieu of colposcopy for cervical neoplasia and female genital schistosomiasis.

Int J Gynaecol Obstet 2021 May;153(2):190-199. Epub 2021 feb 12

PMID: 33316096

Patel P, Rose CE, Kjetland EF, Downs JA, Mbabazi PS, Sabin K, Chege W, Watts DH, Secor WE

Association of schistosomiasis and HIV infections: A systematic review and meta-analysis.

Int J Infect Dis 2021 Jan;102():544-553. Epub 2020 nov 3

PMID: 33157296

Hotez PJ, Harrison W, Fenwick A, Bustinduy AL, Ducker C, Mbabazi PS, Engels D, Kjetland EF

Correction: Female genital schistosomiasis and HIV/AIDS: Reversing the neglect of girls and women.

PLoS Negl Trop Dis 2020 Sep;14(9):e0008725. Epub 2020 sep 1

PMID: 32870910

Maphumulo A, Mahomed O, Vennervald B, Gundersen SG, Taylor M, Kjetland EF

The cost of a school based mass treatment of schistosomiasis in Ugu District, KwaZulu Natal, South Africa in 2012.

PLoS One 2020;15(6):e0232867. Epub 2020 jun 4

PMID: 32497049

Pillay P, Downs JA, Changalucha JM, Brienen EAT, Ramarokoto CE, Leutscher PDC, Vennervald BJ, Taylor M, Kjetland EF, van Lieshout L

Detection of Schistosoma DNA in genital specimens and urine: A comparison between five female African study populations originating from S. haematobium and/or S. mansoni endemic areas.

Acta Trop 2020 Apr;204():105363. Epub 2020 feb 5

PMID: 32035055

Hotez PJ, Harrison W, Fenwick A, Bustinduy AL, Ducker C, Sabina Mbabazi P, Engels D, Floerecke Kjetland E

Female genital schistosomiasis and HIV/AIDS: Reversing the neglect of girls and women.

PLoS Negl Trop Dis 2019 04;13(4):e0007025. Epub 2019 apr 4

PMID: 30946746

Galappaththi-Arachchige HN, Zulu SG, Kleppa E, Lillebo K, Qvigstad E, Ndhlovu P, Vennervald BJ, Gundersen SG, Kjetland EF, Taylor M

Reproductive health problems in rural South African young women: risk behaviour and risk factors.

Reprod Health 2018 Aug 15;15(1):138. Epub 2018 aug 15

PMID: 30111335

Lothe A, Zulu N, Øyhus AO, Kjetland EF, Taylor M

Treating schistosomiasis among South African high school pupils in an endemic area, a qualitative study.

BMC Infect Dis 2018 05 25;18(1):239. Epub 2018 mai 25

PMID: 29801483

Christensen EE, Taylor M, Zulu SG, Lillebo K, Gundersen SG, Holmen S, Kleppa E, Vennervald BJ, Ndhlovu PD, Kjetland EF

Seasonal variations in Schistosoma haematobium egg excretion in school-age girls in rural KwaZulu-Natal Province, South Africa.

S Afr Med J 2018 Mar 28;108(4):352-355. Epub 2018 mar 28

PMID: 29629689

Galappaththi-Arachchige HN, Holmen S, Koukounari A, Kleppa E, Pillay P, Sebitloane M, Ndhlovu P, van Lieshout L, Vennervald BJ, Gundersen SG, Taylor M, Kjetland EF

Evaluating diagnostic indicators of urogenital Schistosoma haematobium infection in young women: A cross sectional study in rural South Africa.

PLoS One 2018;13(2):e0191459. Epub 2018 feb 16

PMID: 29451887

Freer JB, Bourke CD, Durhuus GH, Kjetland EF, Prendergast AJ

Schistosomiasis in the first 1000 days.

Lancet Infect Dis 2018 Jun;18(6):e193-e203. Epub 2017 nov 20

PMID: 29170089

Mbatha JN, Galapaththi-Arachchige HN, Mtshali A, Taylor M, Ndhlovu PD, Kjetland EF, Baay MFD, Mkhize-Kwitshana ZL

Self-sampling for human papillomavirus testing among rural young women of KwaZulu-Natal, South Africa.

BMC Res Notes 2017 Dec 06;10(1):702. Epub 2017 des 6

PMID: 29208043

Mbatha JN, Taylor M, Kleppa E, Lillebo K, Galapaththi-Arachchige HN, Singh D, Kjetland EF, Baay MFD, Mkhize-Kwitshana ZL

High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination.

Infect Dis (Lond) 2017 Aug;49(8):601-608. Epub 2017 apr 12

PMID: 28403727

Galappaththi-Arachchige HN, Amlie Hegertun IE, Holmen S, Qvigstad E, Kleppa E, Sebitloane M, Ndhlovu PD, Vennervald BJ, Gundersen SG, Taylor M, Kjetland EF

Association of Urogenital Symptoms with History of Water Contact in Young Women in Areas Endemic for S. haematobium. A Cross-Sectional Study in Rural South Africa.

Int J Environ Res Public Health 2016 Nov 14;13(11). Epub 2016 nov 14

PMID: 27854250

Baan M, Galappaththi-Arachchige HN, Gagai S, Aurlund CG, Vennervald BJ, Taylor M, van Lieshout L, Kjetland EF

The Accuracy of Praziquantel Dose Poles for Mass Treatment of Schistosomiasis in School Girls in KwaZulu-Natal, South Africa.

PLoS Negl Trop Dis 2016 May;10(5):e0004623. Epub 2016 mai 3

PMID: 27139497

Holmen S, Galappaththi-Arachchige HN, Kleppa E, Pillay P, Naicker T, Taylor M, Onsrud M, Kjetland EF, Albregtsen F

Characteristics of Blood Vessels in Female Genital Schistosomiasis: Paving the Way for Objective Diagnostics at the Point of Care.

PLoS Negl Trop Dis 2016 Apr;10(4):e0004628. Epub 2016 apr 13

PMID: 27073857

Bustinduy AL, Friedman JF, Kjetland EF, Ezeamama AE, Kabatereine NB, Stothard JR, King CH

Expanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for Schistosomiasis.

PLoS Negl Trop Dis 2016 Sep;10(9):e0004946. Epub 2016 sep 22

PMID: 27658198

Pillay P, van Lieshout L, Taylor M, Sebitloane M, Zulu SG, Kleppa E, Roald B, Kjetland EF

Cervical cytology as a diagnostic tool for female genital schistosomiasis: Correlation to cervical atypia and Schistosoma polymerase chain reaction.

Cytojournal 2016;13():10. Epub 2016 apr 20

PMID: 27168759

Jacobson J, Pantelias A, Williamson M, Kjetland EF, Krentel A, Gyapong M, Mbabazi PA, Djirmay AG

Addressing a silent and neglected scourge in sexual and reproductive health in Sub-Saharan Africa by development of training competencies to improve prevention, diagnosis, and treatment of female genital schistosomiasis (FGS) for health workers

Reprod Health, 2022 PMID: 35073965

Jacobson J, Pantelias A, Williamson M, Kjetland EF, Krentel A, Gyapong M, Mbabazi PS, Djirmay AG.

Addressing a silent and neglected scourge in sexual and reproductive health in Sub-Saharan Africa by development of training competencies to improve prevention, diagnosis, and treatment of female genital schistosomiasis (FGS) for health workers

Reprod Health . 2022 Jan 24;19(1):20. doi: 10.1186/s12978-021-01252-2.

Zulu SG, Kjetland EF, Gundersen SG, Taylor M

Prevalence and intensity of neglected tropical diseases (schistosomiasis and soil-transmitted helminths) amongst rural female pupils in Ugu district, KwaZulu-Natal, South Africa

Southern African Journal of Infectious Diseases, 2020

Mazani F, Taylor M, Kjetland EF, Ndhlovu PD

Knowledge and perceptions about schistosomiasis among primary school children and teachers in rural KwaZulu-Natal

Southern African Journal of Infectious Diseases, 2020

Banhela N, Taylor M, Zulu SG, Strabo LS, Kjetland EF, Gundersen SG

Environmental factors influencing the distribution and prevalence of Schistosoma haematobium in school attenders of ILembe and uThungulu Health Districts, KwaZulu-Natal Province, South Africa

Southern African Journal of Infectious Diseases, Volume 32(4), Pages 132-137, 2017

Molvik M, Helland E, Zulu SG, Kleppa E, Lillebo K, Gundersen SG, Kvalsvig JD, Taylor M, Kjetland EF, Vennervald BJ

Co-infection with Schistosoma haematobium and soil-transmitted helminths in rural South Africa.

South African Journal of Science, Volume 113(3-4)Pages 113, 1-6, 2017

Mbabazi P,Vwalika B,Randrianasolo B,Roald B,Ledzinski D,Olowookorun F,Hyera F,Galappaththi HN,Sebitloane M,Taylor M,Mhlanga R,Mabote S,Mocumbi S,Holmen S,Nemungadi T,Ngcobo T,Furumele T,Mushangwe-Mtisi V,Zwane Z,Mkhize-Kwitshana Z,Kjetland EF

Organisation mondiale de la Santé (WHO). Bilharziose génitale chez la femme : Atlas de poche pour les professionnels de santé

WHO/HTM/NTD/2015.4. Geneva: WHO, 49.

Munsami AD, Mitchell C, Lachenicht L, Kvalsvig JD, Kjetland EF, Taylor M

The Role of Socio-Cultural-Cognition in Disease Prevalence and Risky Behaviour among Children: A Conceptual Framework

Journal of AIDS & Clinical Research, 2016, 7:11 DOI: 10.4172/2155-6113.1000631

Doktorgrader
Pavitra Pillay

FGS as an epidemiological risk factor for squamous cell atypia and genital disease in a longitudinal cohort of young women

Disputert:
januar 2021
Hovedveileder:
Myra Taylor
Hashini Nilushika Galappaththi-Arachchige

Reproductive health in young women of rural South Africa endemic of Schistosoma haematobium: Diagnostics and risk factors

Disputert:
oktober 2019
Hovedveileder:
Eyrun Flørecke Kjetland
Sigve Holmen

Computer Image Analysis as a Diagnostic Tool in Female Genital Schistosomiasis

Disputert:
mai 2017
Hovedveileder:
Eyrun Flørecke Kjetland
Joyce Nonhlanhla Mbatha

Genotyping and clearance of high-risk HPV and self-sampling of HIV infected and uninfected young women in KwaZulu-Natal

Disputert:
januar 2017
Hovedveileder:
Zilungile Kwitshana
Deltagere
  • Ameli Trope Forsker (annen finansiering)
  • Solrun Søfteland Doktorgradsstipendiat (annen finansiering)
  • Saloshni Naidoo Forsker (annen finansiering)
  • Costas Balas Forsker (annen finansiering)
  • Santiago Martinez Forsker (annen finansiering)
  • Teresa Norris Prosjektdeltaker
  • Margaret Gyapong Forsker (annen finansiering)
  • Lisette Van Lieshout Forsker (annen finansiering)
  • Takalani Nemungadi Doktorgradsstipendiat (annen finansiering)
  • Hanne Haaland Forsker (annen finansiering)
  • Nonhlanhla Mbatha Forsker (annen finansiering)
  • Sigve Holmen Forsker (annen finansiering)
  • Pavitra Pillay Forsker (annen finansiering)
  • Hashini Nilushika Galappaththi-Arachchige Doktorgradsstipendiat (annen finansiering)
  • Patricia Doris Ndhlovu Forsker (annen finansiering)
  • Birgitte Jyding Vennervald Forsker (annen finansiering)
  • Svein Gunnar Gundersen Forsker (annen finansiering)
  • Motshedisi Sebitloane Forsker (annen finansiering)
  • Myra Taylor Forsker (annen finansiering)
  • Hanna Sortevik Haaland Forsker (annen finansiering)
  • Samantha Page Forsker (annen finansiering)
  • Hashini Galappaththi Doktorgradsstipendiat (annen finansiering)
  • Motshedisi Hanna Sebitloane Forsker (annen finansiering)
  • Eyrun Flørecke Kjetland Forskningsgruppeleder

eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT

Alle henvendelser rettes til eRapport

Personvern  -  Informasjonskapsler